Skip to main content

Table 2 Organ Gb3a levels 26 weeks postinjection (Experiment 1)

From: α-Galactosidase A-Tat Fusion Enhances Storage Reduction in Hearts and Kidneys of Fabry Mice

Gb3 levels (nmol/mg protein)

 

Liver

Spleen

Heart

Kidney

Lung

PBS

13.4 ± 0.8 (n = 7)

18.4 ± 1.8 (n = 4)

8.8 ± 1.0 (n = 6)

29.8 ± 1.5 (n = 7)

59.1 ± 6.5 (n = 7)

LV/enGFP

15.4 ± 2.0 (n = 5)

11.9 ± 1.3 (n = 4)

5.1 ± 0.5 (n = 3)

28.6 ± 7.1 (n = 5)

8.3 ± 1.4b (n = 3)

LV/α-gal A

1.0 ± 0.1 (n = 8)

2.8 ± 1.2 (n = 6)

1.3 ± 0.1 (n = 7)

17.2 ± 1.3 (n = 9)

12.4 ± 2.2 (n = 7)

LV/α-gal A-Tat

0.9 ± 0.2 (n = 8)

3.0 ± 0.6 (n = 8)

0.8 ± 0.1c (n = 6)

8.2 ± 1.7d (n = 9)

10.2 ± 0.7 (n = 7)

WTe

0.6 ± 0.2 (n = 5)

1.3 ± 0.1 (n = 5)

0.2 ± 0.1 (n = 4)

4.9 ± 1.6 (n = 5)

2.3 ± 0.6 (n = 3)

  1. aGb3, globotriaosylceramide.
  2. bLittle sample to analyze because of technical issues.
  3. cP < 0.05.
  4. dP < 0.01 vs LV/α-gal A group.
  5. eWT, wild type.